https://theglp1academy.com/blogs Plain-English, cited articles on GLP-1 nutrition, muscle preservation, side effects, and the newest weight-loss research. en-us Tue, 21 Jul 2026 00:00:00 GMT https://theglp1academy.com/blogs/how-much-weight-can-you-lose-on-foundayo https://theglp1academy.com/blogs/how-much-weight-can-you-lose-on-foundayo Tue, 21 Jul 2026 00:00:00 GMT Foundayo (orforglipron) is the first oral, non-peptide GLP-1 pill FDA-approved for weight loss (April 1, 2026). Its pivotal trial showed 7.4% to 11.1% average weight loss over 72 weeks depending on dose, versus 2.1% on placebo, with no food or water restrictions. https://theglp1academy.com/blogs/can-semaglutide-help-people-with-schizophrenia-lose-weight https://theglp1academy.com/blogs/can-semaglutide-help-people-with-schizophrenia-lose-weight Fri, 17 Jul 2026 00:00:00 GMT A CAMH trial (NCT05333003) is testing weekly semaglutide against placebo in 92 adults with schizophrenia whose antipsychotic-induced weight gain did not respond to metformin, tracking psychiatric symptoms and cognition alongside weight. Active, not recruiting - no results yet. https://theglp1academy.com/blogs/retatrutide-and-triumph-1-what-we-know-so-far https://theglp1academy.com/blogs/retatrutide-and-triumph-1-what-we-know-so-far Thu, 16 Jul 2026 00:00:00 GMT Retatrutide is Eli Lilly's experimental triple-hormone-receptor agonist (GLP-1, GIP, glucagon) for obesity. Its Phase 3 trial TRIUMPH-1 enrolled 2,335 adults and finished in April 2026 but has no results posted yet. Its Phase 2 trial showed up to 24.2% weight loss at 48 weeks - here is the full picture. https://theglp1academy.com/blogs/can-maritide-treat-heart-failure-and-obesity https://theglp1academy.com/blogs/can-maritide-treat-heart-failure-and-obesity Sat, 11 Jul 2026 00:00:00 GMT Amgen's Phase 3 MARITIME-HF trial is testing MariTide, an investigational once-monthly GLP-1 agonist and GIP antagonist, in about 5,056 people with obesity and heart failure with preserved or mildly reduced ejection fraction. Recruiting now - no results yet. https://theglp1academy.com/blogs/can-tirzepatide-help-breast-cancer-survivors-lose-weight https://theglp1academy.com/blogs/can-tirzepatide-help-breast-cancer-survivors-lose-weight Thu, 09 Jul 2026 00:00:00 GMT Rutgers is running FITWISE, a Phase 2 trial testing weekly tirzepatide in 40 adults with early-stage HR+/HER2- breast cancer and obesity, tracking weight loss, safety, and 3-year cancer recurrence. Recruiting now - no results yet. https://theglp1academy.com/blogs/can-tirzepatide-help-people-with-type-1-diabetes-and-obesity https://theglp1academy.com/blogs/can-tirzepatide-help-people-with-type-1-diabetes-and-obesity Fri, 03 Jul 2026 00:00:00 GMT Eli Lilly's SURPASS-T1D-2 trial is testing weekly tirzepatide against placebo in adults with type 1 diabetes and obesity, a group usually excluded from GLP-1 weight-loss trials over hypoglycemia risk. No results yet - here is the full design. https://theglp1academy.com/blogs/tirzepatide-vs-semaglutide-for-hfpef-whats-being-studied https://theglp1academy.com/blogs/tirzepatide-vs-semaglutide-for-hfpef-whats-being-studied Sat, 04 Jul 2026 00:00:00 GMT Brigham and Women's Hospital is comparing tirzepatide and semaglutide in ~26,000 people with type 2 diabetes and heart failure with preserved ejection fraction using insurance claims data. No results are posted yet - here is the full design and its limits. https://theglp1academy.com/blogs/does-tirzepatide-protect-muscle-and-bone-in-older-adults https://theglp1academy.com/blogs/does-tirzepatide-protect-muscle-and-bone-in-older-adults Thu, 02 Jul 2026 00:00:00 GMT A Wake Forest University pilot trial (GLOW) is giving 40 adults over 65 weekly tirzepatide plus high-protein counseling for 9 months, tracking lean mass, bone density, and walking speed. No results yet - here is the full design. https://theglp1academy.com/blogs/semaglutide-tirzepatide-biological-aging https://theglp1academy.com/blogs/semaglutide-tirzepatide-biological-aging Tue, 30 Jun 2026 00:00:00 GMT A 66-person trial in China is testing whether semaglutide or tirzepatide slow epigenetic aging, measured by DNA methylation testing, more than metformin. Recruiting now - no results yet. https://theglp1academy.com/blogs/bariatric-surgery-vs-semaglutide-vs-tirzepatide https://theglp1academy.com/blogs/bariatric-surgery-vs-semaglutide-vs-tirzepatide Mon, 29 Jun 2026 00:00:00 GMT A Cleveland Clinic trial of 125 adults is running the first head-to-head comparison of bariatric surgery against semaglutide and tirzepatide. Underway now - no weight-loss results yet, here is the full design. https://theglp1academy.com/blogs/can-high-protein-diets-stop-glp-1-muscle-loss https://theglp1academy.com/blogs/can-high-protein-diets-stop-glp-1-muscle-loss Fri, 26 Jun 2026 00:00:00 GMT LEAN-PRO GLP-1, a randomized trial of 130 adults in Greece, is testing whether a high-protein diet preserves more muscle than standard counseling during GLP-1 treatment. Recruiting now - no results yet, here is the full design. https://theglp1academy.com/blogs/semaglutide-vs-tirzepatide-which-protects-the-heart-more https://theglp1academy.com/blogs/semaglutide-vs-tirzepatide-which-protects-the-heart-more Thu, 25 Jun 2026 00:00:00 GMT A 2026 real-world cohort study of 21,250 patients found semaglutide cut major cardiovascular events by 22-29% compared with tirzepatide. The study was funded by Novo Nordisk - here is what it does and does not show. https://theglp1academy.com/blogs/tirzepatide-dulaglutide-kidney-surpass-cvot https://theglp1academy.com/blogs/tirzepatide-dulaglutide-kidney-surpass-cvot Tue, 16 Jun 2026 00:00:00 GMT A pre-specified analysis of the SURPASS-CVOT trial in 13,299 patients found tirzepatide cut major kidney events by 23% versus dulaglutide. The benefit held across both lower-risk and higher-risk kidney disease groups. Eli Lilly funded the trial. https://theglp1academy.com/blogs/tirzepatide-vs-semaglutide-weight-loss https://theglp1academy.com/blogs/tirzepatide-vs-semaglutide-weight-loss Thu, 18 Jun 2026 00:00:00 GMT Two independent 2025 meta-analyses covering 142,000+ patients show tirzepatide (Mounjaro/Zepbound) outperforms semaglutide (Wegovy/Ozempic) by roughly 4 kg on average. The gap grows at higher doses. Real-world data and key caveats included. https://theglp1academy.com/blogs/semaglutide-heart-protection-afib-ami-meta-analysis https://theglp1academy.com/blogs/semaglutide-heart-protection-afib-ami-meta-analysis Sat, 20 Jun 2026 00:00:00 GMT A 2025 meta-analysis of 10 RCTs and 22,937 patients found semaglutide reduces heart attack risk by 28%, atrial fibrillation risk by 21%, and angina risk by 23%. Benefits were strongest in patients over 60 and those on therapy for more than 52 weeks. https://theglp1academy.com/blogs/how-much-muscle-do-you-lose-on-glp-1 https://theglp1academy.com/blogs/how-much-muscle-do-you-lose-on-glp-1 Tue, 23 Jun 2026 00:00:00 GMT A 2025 meta-analysis of 22 RCTs and 2,258 patients found roughly 24% of weight lost on GLP-1 medications is lean muscle. What the data shows for semaglutide, tirzepatide, and liraglutide - and how to protect your muscle.